Clinical trial
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
NCT00241670 · medac GmbH, Industry · Completed
Key facts
| NCT number | NCT00241670 |
|---|---|
| Title | Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid |
| Official title | Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection |
| Lead sponsor | medac GmbH, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Cancer, Brain Tumors, Cancer of Brain, Primary Brain Tumors, Brain Tumor, Primary |
| Intervention type | Drug |
| Interventions | 5-aminolevulinic acid (5-ALA) |
| Enrollment | 415 |
| Start date | Oct 1, 1999 |
| Primary completion | Jul 1, 2004 |
| First posted | Oct 19, 2005 |
| Last update posted | Apr 26, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: